EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische Studie

Danburstotug, an anti‐ PD ‐ L1 antibody, in relapsed/refractory extra‐nodal natural killer/T‐cell lymphoma: The phase 2 DISTINKT study

Won Seog Kim iD, Seok Jin Kim iD, Jae-Cheol Jo iD, Sang Eun Yoon iD, Youngil Koh iD, Deok-Hwan Yang iD, Dok Hyun Yoon iD, Junhun Cho iD, Sung Young Lee iD, Suyeon Kim iD, Seongyeon Kang iD, Woochan Hwang iD und 5 weitere

British Journal of Haematology · 2026

DOI: 10.1111/bjh.70742 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift British Journal of Haematology, 2026. Verfasst von Won Seog Kim und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: B7-H1 Antigen, Lymphoma, Extranodal NK-T-Cell, Immune Checkpoint Inhibitors, Antineoplastic Agents, Immunological. Die Arbeit nennt 37 Literaturangaben. Gefördert von: ImmuneOncia Therapeutics Inc. (Seoul, Republic of Korea [South]).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Relapsed/refractory extra‐nodal natural killer/T‐cell lymphoma (R/R ENKTL) has limited treatment options. Danburstotug, an antibody targeting programmed death‐ligand 1 (PD‐L1), was evaluated in adults with R/R ENKTL in a phase 2, open‐label study (NCT04414163). Danburstotug 20 mg/kg was administered intravenously every 2 weeks up to 52 cycles, disease progression or unacceptable toxicity. In the full analysis set ( n = 19), objective response rate (ORR; primary end‐point) was 78.9% (95% confidence interval 54.4–94.0); complete response (CR) rate was 63.2% (38.4–83.7); 76.9% of participants maintained responses; and 90.9% of participants maintained CR for 2 years. In the intention‐to‐treat population ( n = 23), median progression‐free survival (PFS) was 29.4 months (12.0–46.9; 2‐year PFS rate 62.1%); and median overall survival was 40.2 months (25.1–55.4; 2‐year overall survival rate 77.9%). Treatment‐emergent adverse events occurred in 91.3% of 23 participants (73/83 events were grade 1/2); grade 3 serious treatment‐related adverse events comprised liver injury and uveitis (one participant each). High PD‐L1 membrane specificity (MS) was associated with greater ORR, CR rate and PFS versus low PD‐L1 MS. In tumour immune microenvironment assessments, clinical benefit was observed across immune tolerance and immune evasion subtypes, despite lower PD‐L1 expression in immune evasion‐B. Danburstotug demonstrated robust, durable efficacy and manageable safety. PD‐L1 MS showed potential as a predictive biomarker.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenLymphoma, Extranodal NK-T-CellImmune Checkpoint InhibitorsAntineoplastic Agents, ImmunologicalHumansFemaleMaleMiddle AgedAgedAdultRecurrenceAged, 80 and over

Stichwörter der Autor:innen

anti‐PD‐L1 antibodyclinical trialdanburstotugextra‐nodal natural killer/T‐cell lymphomaimmunotherapyrelapsed and refractory

Substanzen

B7-H1 AntigenCD274 protein, humanImmune Checkpoint InhibitorsAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea.
  • Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, Jeollanam-do, Republic of Korea.
  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

ORCID-Profile: Won Seog Kim, Seok Jin Kim, Jae-Cheol Jo, Sang Eun Yoon, Youngil Koh, Deok-Hwan Yang, Dok Hyun Yoon, Junhun Cho, Sung Young Lee, Suyeon Kim, Seongyeon Kang, Woochan Hwang, Hyukjung Kim, Hwi-Yeol Yun, Jihyun Jeon, Chul Ahn, Heung Tae Kim

Förderung

  • ImmuneOncia Therapeutics Inc. (Seoul, Republic of Korea [South])

Zitieren

APA

Kim, W. S., Kim, S. J., Jo, J. C., Yoon, S. E., Koh, Y., Yang, D. H., Yoon, D. H., Cho, J., Lee, S. Y., Kim, S., Kang, S., Hwang, W., Kim, H., Yun, H. Y., Jeon, J., Ahn, C., & Kim, H. T. (2026). Danburstotug, an anti‐ PD ‐ L1 antibody, in relapsed/refractory extra‐nodal natural killer/T‐cell lymphoma: The phase 2 DISTINKT study. British Journal of Haematology. https://doi.org/10.1111/bjh.70742

Vancouver

Kim WS, Kim SJ, Jo JC, Yoon SE, Koh Y, Yang DH, et al. Danburstotug, an anti‐ PD ‐ L1 antibody, in relapsed/refractory extra‐nodal natural killer/T‐cell lymphoma: The phase 2 DISTINKT study. British Journal of Haematology. 2026. doi:10.1111/bjh.70742

BibTeX
@article{Kim2026,
  author = {Kim, Won Seog and Kim, Seok Jin and Jo, Jae-Cheol and Yoon, Sang Eun and Koh, Youngil and Yang, Deok-Hwan and Yoon, Dok Hyun and Cho, Junhun and Lee, Sung Young and Kim, Suyeon and Kang, Seongyeon and Hwang, Woochan and Kim, Hyukjung and Yun, Hwi-Yeol and Jeon, Jihyun and Ahn, Chul and Kim, Heung Tae},
  title = {Danburstotug, an anti‐ PD ‐ L1 antibody, in relapsed/refractory extra‐nodal natural killer/T‐cell lymphoma: The phase 2 DISTINKT study},
  journal = {British Journal of Haematology},
  year = {2026},
  doi = {10.1111/bjh.70742}
}
Kostenlos starten →